CD47 antagonists can also enhance NK-mediated antibody-dependent cytotoxicity (ADCC) and complement-mediated cytotoxicity, promote cancer cell apoptosis, reduce cancer cell proliferation, and prevent tumor cell migration [211,212,213]. Here, CD47 is linked to cancer.